Ning Zhou1, Jianzhou Li1, Yimin Zhang1, Juan Lu1, Ermei Chen1, Weibo Du1, Jie Wang1, Xiaoping Pan1, Danhua Zhu1, Ying Yang1, Yu Chen2, Hongcui Cao1, Lanjuan Li3. 1. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Collaborative Innovation Center for Diagnosis and Treatment of Infection Diseases, Zhejiang University, Hangzhou, China. 2. Zhejiang Academy of Traditional Chinese Medicine, Hangzhou, China. 3. State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, School of Medicine, Zhejiang University, Hangzhou, China; Collaborative Innovation Center for Diagnosis and Treatment of Infection Diseases, Zhejiang University, Hangzhou, China. Electronic address: ljli@zju.edu.cn.
Abstract
BACKGROUND & AIMS: Extracorporeal blood purification systems for supportive therapy of liver failure are widely used. We developed a novel blood purification system, named Li's artificial liver system (Li-ALS), which couples low-volume plasma exchange (low-volume PE) with plasma filtration adsorption (PFA). This study aims to evaluate the efficacy of our novel system in pigs with acute liver failure (ALF). METHODS: Thirty-two pigs were infused with D-galactosamine (1.3g/kg) to induce ALF. All animals were equally and randomly divided into four groups: the ALF control group received intensive care, the PFA group underwent five hour plasma recycling filtration and adsorption purification, the low-volume PE group received one hour low-volume PE, and the Li-ALS group underwent one hour low-volume PE, followed by five hour PFA. Intervention was initiated 36hours after drug administration. The efficacy of each treatment was assessed by survival time and improvement in hematological, biochemical, and immunohistological parameters. RESULTS: Pigs in the Li-ALS group survived longer than those in the other groups (p<0.001, ALF control: 60±2h; PFA group: 74±2h; low-volume PE group: 75±2h; and Li-ALS group: 90±3h). Liver enzyme, bilirubin, bile acid and blood ammonia levels were decreased significantly after Li-ALS treatment, and increases in inflammatory cytokines were ameliorated. A higher hepatocyte regeneration index was also observed in the Li-ALS group. CONCLUSION: Our novel Li-ALS could expedite liver regeneration and improve survival time; hence, it could be promising for treating ALF.
BACKGROUND & AIMS: Extracorporeal blood purification systems for supportive therapy of liver failure are widely used. We developed a novel blood purification system, named Li's artificial liver system (Li-ALS), which couples low-volume plasma exchange (low-volume PE) with plasma filtration adsorption (PFA). This study aims to evaluate the efficacy of our novel system in pigs with acute liver failure (ALF). METHODS: Thirty-two pigs were infused with D-galactosamine (1.3g/kg) to induce ALF. All animals were equally and randomly divided into four groups: the ALF control group received intensive care, the PFA group underwent five hour plasma recycling filtration and adsorption purification, the low-volume PE group received one hour low-volume PE, and the Li-ALS group underwent one hour low-volume PE, followed by five hour PFA. Intervention was initiated 36hours after drug administration. The efficacy of each treatment was assessed by survival time and improvement in hematological, biochemical, and immunohistological parameters. RESULTS:Pigs in the Li-ALS group survived longer than those in the other groups (p<0.001, ALF control: 60±2h; PFA group: 74±2h; low-volume PE group: 75±2h; and Li-ALS group: 90±3h). Liver enzyme, bilirubin, bile acid and blood ammonia levels were decreased significantly after Li-ALS treatment, and increases in inflammatory cytokines were ameliorated. A higher hepatocyte regeneration index was also observed in the Li-ALS group. CONCLUSION: Our novel Li-ALS could expedite liver regeneration and improve survival time; hence, it could be promising for treating ALF.
Authors: Harvey S Chen; Dong Jin Joo; Mohammed Shaheen; Yi Li; Yujia Wang; Jian Yang; Clara T Nicolas; Kelly Predmore; Bruce Amiot; Gregory Michalak; Taofic Mounajjed; Jeff Fidler; Walter K Kremers; Scott L Nyberg Journal: Hepatology Date: 2018-12-27 Impact factor: 17.425
Authors: Lei Cai; Jun Weng; Lei Feng; Guolin He; Jiasheng Qin; Zhi Zhang; Yang Li; Qing Peng; Zesheng Jiang; Mingxin Pan; Yi Gao Journal: Biomed Res Int Date: 2016-12-21 Impact factor: 3.411
Authors: YiMin Zhang; Li Shao; Ning Zhou; JianZhou Li; Yu Chen; Juan Lu; Jie Wang; ErMei Chen; ZhongYang Xie; LanJuan Li Journal: Can J Gastroenterol Hepatol Date: 2018-04-12
Authors: Lei Feng; Lei Cai; Guo-Lin He; Jun Weng; Yang Li; Ming-Xin Pan; Ze-Sheng Jiang; Qing Peng; Yi Gao Journal: World J Gastroenterol Date: 2017-11-14 Impact factor: 5.742